<DOC>
	<DOCNO>NCT01136863</DOCNO>
	<brief_summary>FEVER investigator-designed , prospective , multicentre , double-bind , randomize , placebo-controlled , parallel-group trial . The primary objective compare long-term effect incidence fatal non-fatal stroke ( secondarily cardiovascular event ) administer small dose calcium antagonist felodipine ( 5 mg day ) placebo , hypertensive patient whose blood pressure preliminarily reduce administer low-dose diuretic ( hydrochlorothiazide,12.5 mg day ) continue association felodipine placebo , throughout trial .</brief_summary>
	<brief_title>Felodipine Event Reduction Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<criteria>SBP 210 mmHg less DBP less 115 mmHg antihypertensive treatment ; SBP 160210 mmHg DBP 95115 mmHg untreated . Presence least one two risk factor cardiovascular disease Informed consent obtain stroke myocardial infarction previous 6 month ; secondary hypertension ; unstable angina ; cardiomyopathy significant valvular disease ; serum creatinine great 178 mmol/l ( 2.0 mg/dl ) ; gout ; uncontrolled diabetes ( fast plasma glucose &gt; 10 mmol/l , 180 mg/dl despite therapy ) ; serious pulmonary hepatic disease ; know contraindication study drug ; unwillingness cooperate</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>hypertension</keyword>
	<keyword>felodipine</keyword>
	<keyword>moderate high risk patient</keyword>
</DOC>